Car with dual-variable domain and enhanced TCR-signaling targeting CT-RCC-1 peptide and methods of use
Antibodies and CARs with Dual-variable-domain and Enhanced TCR-signaling targeting the CT-RCC-1 peptide enhance T-cell activation to effectively treat RCC by specifically killing cancer cells, addressing the need for improved late-stage RCC treatments.
WO2026148120A2PCT designated stage Publication Date: 2026-07-09THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +1
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
- Filing Date
- 2025-12-31
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
There is a need for effective treatment options, particularly for late-stage renal cell carcinoma (RCC), as the 5-year survival rate for metastatic RCC is low, and existing treatments do not adequately address the progression of metastasis in localized tumors.
Method used
Development of antibodies and chimeric antigen receptors (CARs) with Dual-variable-domain and Enhanced TCR-signaling (CADETs) that specifically target the CT-RCC-1 peptide, enhancing T-cell activation and killing of RCC cells by modifying immune cells to express these receptors.
Benefits of technology
The CARs and CADETs effectively target and kill RCC cells, offering a potential therapeutic approach with enhanced T-cell signaling, potentially improving treatment outcomes for RCC patients.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025061839_09072026_PF_FP_ABST
Abstract
Antibodies and constructs, including chimeric antigen receptors, T cell or NK cell engagers, or chimeric antigen receptor (CAR) with Dual-variable-domain and Enhanced TCR-signaling (CADETs) targeting CT-RCC-1 peptide are provided. Also provided are modified immune cells expressing a disclosed CADET and methods of their use for treating renal cell carcinoma.
Need to check novelty before this filing date? Find Prior Art